Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14867327 | 1.00 | MEN1 (0.47) | MEN1KMT2ACYP3A4ALOX15ALDH1A1 | |
| SCHEMBL10696498 | 0.81 | MEN1 (0.40) | MEN1KMT2ACYP3A4ALOX15ALDH1A1 | |
| SCHEMBL16357610 | 0.79 | ALDH1A1 (0.50) | MEN1KMT2ACYP3A4ALOX15ALDH1A1 | |
| SCHEMBL5306831 | 0.79 | MEN1 (0.39) | MEN1KMT2ACYP3A4ALOX15ALDH1A1 | |
| SCHEMBL94185 | 0.79 | MEN1 (0.39) | MEN1KMT2ACYP3A4ALOX15ALDH1A1 | |
| SCHEMBL464975 | 0.79 | MEN1 (0.39) | MEN1KMT2ACYP3A4ALOX15ALDH1A1 | |
| SCHEMBL5604094 | 0.79 | MEN1 (0.39) | MEN1KMT2ACYP3A4ALOX15ALDH1A1 | |
| SCHEMBL8433661 | 0.78 | MEN1 (0.38) | MEN1KMT2ACYP3A4ALOX15ALDH1A1 | |
| SCHEMBL15255183 | 0.76 | MEN1 (0.37) | MEN1KMT2ACYP3A4ALOX15ALDH1A1 | |
| SCHEMBL15257171 | 0.76 | MEN1 (0.37) | MEN1KMT2ACYP3A4ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9872514-B2 | Compounds, compositions, and methods for reducing or eliminating bitter taste | CHROMOCELL CORPORATION (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170000178-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE | CHROMOCELL CORP (US) | 2017-01-05 | — | — | US | disclosed |
| US-9408407-B2 | Compounds, compositions, and methods for reducing or eliminating bitter taste | CHROMOCELL CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150237900-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE | CHROMOCELL CORP (US) | 2015-08-27 | — | — | US | disclosed |
| US-8865779-B2 | Compounds, compositions, and methods for reducing or eliminating bitter taste | CHROMOCELL CORPORATION (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130096209-A1 | Compounds, Compositions, And Methods For Reducing Or Eliminating Bitter Taste | KRAFT FOODS GLOBAL BRANDS LLC (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000178-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE | TAS2R5, TAS2R20, TAS2R10 | MEN1 347/4885KMT2A 2441/4885CYP3A4 3973/4885 |
| US-20150237900-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE | TAS2R5, TAS2R20, TAS2R10 | MEN1 347/4885KMT2A 2441/4885CYP3A4 3973/4885 |
| US-20130096209-A1 | Compounds, Compositions, And Methods For Reducing Or Eliminating Bitter Taste | TAS2R5, TAS2R20, TAS2R10 | MEN1 347/4885KMT2A 2441/4885CYP3A4 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.